Logo

Insmed's Brensocatib Receives the US FDA's Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis

Share this

Insmed's Brensocatib Receives the US FDA's Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis

Shots:

  • The BTD is based on P-II WILLOW study assessing brensocatib vs PBO in adults with NCFBE for reducing exacerbations
  • Insmed expects to initiate a P-III program for brensocatib in bronchiectasis in the H2’21
  • Brensocatib is a novel oral- reversible DPP1 inhibitor- currently being developed for the treatment of bronchiectasis and other inflammatory diseases

 ­ Ref: PRNewswire | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions